Notes

The concept of longevity medicine under the tuyere: the market value of 10 concept stocks has soared by more than 20 billion since July
Hemorrhoids

"The biggest investment opportunity in the next decade is companies committed to delaying human death. In 2025, the market will reach US $600 billion and human health life will soon reach 100 years old," Bank of America Merrill Lynch said in a report.
At present, in China, where aging is gradually emerging, the blue ocean of "longevity medicine" is setting off a huge wave, attracting many companies to search for gold.
According to choice data, as of July 29, 10 stocks had been included in the concept stocks of "longevity medicine", including jindawei, which is popular due to the listing of NMN products this month, as well as some NMN raw material manufacturers and nicotinamide manufacturers.
Stock market value soared
Many companies are suggested by investors to do NMN
"As long as the plant technology of the company is advanced and redundant, there should be no problem if we want to produce NMN?"
On July 29, another listed company received the suggestion of "producing NMN" from investors. On this day alone, more than 5 listed companies such as YABEN chemical, jindawei, Fengyuan pharmaceutical and Xinhua Pharmaceutical were asked about NMN by investors.
This is because on July 8, doctor's best, a U.S. holding subsidiary of jindawei, launched a product called "NMN anti-aging doctor's best / Dobbs DRB nad".
From early July to July 29, 7 of the above 10 stocks rose by more than 10%, of which jindawei rose by 100.92%. These 10 stocks also jointly won 24 trading boards in this range, of which jindawei accounted for 9.
Among the above "longevity medicine" concept stocks, youa shares said on July 13 that the company officially signed a cooperation agreement with herbalmax's Chinese agents at the beginning of this year, and the herbalmax brand has been sold in youahai outsourcing and offline experience stores on the company's e-commerce platform.
On July 14, in response to investors, Yinxi technology said that the company shares in Suzhou pilot Biotechnology Co., Ltd., which is shared by Sun company β- Nicotinamide mononucleotide (NMN) related products are currently in the early stage of research and development, and there are major uncertainties about the success of research and development in the future.
On July 14, Zhongsheng pharmaceutical said on the investor interaction platform that the company's wholly-owned subsidiary is conducting NMN（ β- The development of nicotinamide mononucleotide) is currently in the pilot stage.
Previously, in October 2019, YABEN chemical announced that the company planned to use its own funds or self raised funds of 1.25 billion yuan to build the API project, in which the enzyme preparation and green research institute project involved should develop and produce NMN and other biological enzyme preparations and related biotechnology products.
In addition, brother technology, red sun, China Resources Shuanghe, Erkang pharmaceutical, etc. were also included in the concept stocks of "longevity medicine" due to the production of nicotinamide and niacin.
My Website: https://www.hemorrhoids.shop/patented-product